Stem Cell Network

Stem Cell Network

The Stem Cell Network was founded in 2001 as a Canadian federally funded research consortium, led by CEO Dr. Jennifer MacKenzie and Scientific Director Dr. Michael Edel. It coordinates stem cell and regenerative medicine research across universities, hospitals, and industry partners, primarily in Canada. The network's strategy centers on funding early-stage research through peer-reviewed grants, supporting clinical trials, and fostering commercialization of stem cell therapies. Key focus areas include cardiovascular disease, diabetes, neurodegenerative disorders, and musculoskeletal repair. It has supported over 200 research projects and trials, with partners spanning academic centers like the University of Toronto and McGill University. The Stem Cell Network reports a funding portfolio of over $100 million since inception from federal sources and industry contributions. It employs a small team concentrated in Ottawa, operating without a traditional asset management structure. No additional offices or philanthropic vehicles are formally disclosed. The Stem Cell Network's structural differentiator is its role as a publicly funded innovation intermediary rather than a private capital pool — it does not manage external capital or charge management fees. Its mandate is to de-risk regenerative medicine technologies to the point where commercial partners can license or spin out.